LifeVantage (LFVN) Investor Presentation summary

Mission and business overview

• Focuses on wellness and healthy living through science-based, patented nutrigenomic products that activate the body's natural processes.

• Operates a direct sales model with approximately 121,000 active consumers in 20 global markets, supported by independent consultants.

• 70% of revenue is generated from monthly subscriptions, providing recurring income and customer retention.

• Maintains a highly variable cost structure and minimal capital requirements, resulting in strong free cash flow.

• Returned over $19 million to shareholders since the start of fiscal 2024.

Product innovation and market positioning

• Offers patented products like Protandim Nrf2 Synergizer, TrueScience Liquid Collagen, and the MindBody GLP-1 System, targeting oxidative stress, collagen production, and weight management.

• Acquired LoveBiome, expanding into the microbiome health sector with the launch of P84, a comprehensive gut health solution.

• Product launches and enhancements are aligned with major wellness trends, including gut health and natural GLP-1 support.

• Products are supported by peer-reviewed research and a scientific advisory board.

• Subscription-based product stacks encourage higher consumer spending and consultant earnings.

Financial performance and outlook

• Fiscal 2025 revenue reached $228.5 million, up 14.2% from the prior year, with adjusted EBITDA of $22.1 million (9.7% margin).

• Debt-free balance sheet with $13.1 million in cash and $26.2 million in working capital as of September 30, 2025.

• Market capitalization of approximately $79 million and enterprise value of $65.8 million.

• FY26 revenue guidance midpoint projects a 2% increase over FY25.

• Strong capital allocation with $9.6 million in dividends and $10.2 million in share repurchases since fiscal 2024.